How mRNA Technology Is Being Used to Create Personalized Cancer Vaccines Based on Tumor-Specific Peptides | Research

The takeaway

This review examines how mRNA vaccine technology — the same platform behind COVID-19 vaccines — is being adapted to deliver personalized cancer-fighting peptide antigens, with emphasis on computational methods for selecting the right neoantigen targets.

mRNA: ideal platform for personalized neoantigen immunotherapy
Combining rapid manufacturing with computational neoantigen peptide selection to create patient-specific cancer vaccines targeting tumor mutations

What the researchers found

The review establishes mRNA as an ideal platform for personalized neoantigen cancer immunotherapy due to its versatility and rapid development potential. Key neoantigen selection criteria include: peptide presentation on HLA molecules, HLA-peptide binding affinity, and T cell receptor recognition — all assessed through advanced computational algorithms using next-generation sequencing data. The review covers both shared antigens (common across patients) and individual neoantigens (unique to each patient's tumor), discussing the computational workflows, design considerations for immunogenicity and stability, and clinical trial evidence supporting this approach.

Why it matters

Personalized mRNA cancer vaccines represent one of the most promising new approaches to cancer treatment. Understanding how to select the right peptide targets is the critical bottleneck. This review synthesizes the computational and biological principles that guide neoantigen selection, providing a roadmap for the field. With major clinical trials underway (Moderna/Merck's mRNA-4157 for melanoma, BioNTech's individualized vaccines), the stakes are enormous.

The numbers in context

Covers: shared + individual neoantigens · HLA-peptide-TCR complex formation · Next-gen sequencing workflows · Multiple clinical trials reviewed

How the study worked

Comprehensive review of the development and clinical application of mRNA-based cancer vaccines, covering computational workflows for neoantigen identification and prioritization, antigen target strategies (tumor-associated vs. tumor-specific), mRNA design considerations, and clinical trial data. Focuses on therapeutic (not preventive) cancer vaccines.

Who was studied

Review of mRNA cancer vaccine technology focusing on neoantigen peptide selection, computational workflows, and clinical trial applications

What this study cannot tell us

As a review, no new experimental data is presented. The field is rapidly evolving, so some discussed methods may already be superseded. The review acknowledges that neoantigen prediction remains imperfect — many predicted neoantigens fail to elicit immune responses in practice. Clinical outcomes from mRNA cancer vaccine trials are still early and often combined with other immunotherapies, making it difficult to isolate the vaccine's contribution.

How to read the evidence

This is a comprehensive review article synthesizing preclinical research, computational methodology, and early clinical trial data. While it provides an authoritative overview, the underlying clinical evidence for mRNA cancer vaccines is still early-stage, with pivotal trial results pending.

When this study was published

Published in 2025, this review captures the current state of a rapidly moving field. mRNA cancer vaccines are in active clinical development, with several late-stage trials expected to report results in the near future.

The bigger picture

mRNA cancer vaccines are at the intersection of three rapidly advancing fields: mRNA technology (proven by COVID-19 vaccines), computational biology (increasingly accurate antigen prediction), and cancer immunotherapy (checkpoint inhibitors providing the immunological foundation). The convergence of these fields has created unprecedented momentum for personalized cancer vaccines, with potential to transform treatment for melanoma, pancreatic cancer, and other difficult malignancies.

Questions still open

Will mRNA cancer vaccines achieve clinical success as monotherapies, or will they primarily serve as combination partners with checkpoint inhibitors?
How can neoantigen prediction algorithms be improved to reduce the high false-positive rate in identifying peptide targets?
Can the manufacturing and delivery speed of personalized mRNA vaccines be reduced enough to be practical for rapidly progressing cancers?

Common questions

How does an mRNA cancer vaccine work differently from a COVID vaccine?

Both use the same basic technology — mRNA instructions that tell your cells to make a specific protein so the immune system can learn to recognize it. COVID vaccines encode the viral spike protein. Cancer vaccines encode peptide fragments (neoantigens) from a patient's specific tumor mutations. The immune system then learns to recognize and attack cells displaying those tumor-specific peptides. Cancer vaccines are therapeutic (treating existing disease) rather than preventive.

Why is choosing the right peptide target so important for cancer vaccines?

A typical tumor may have hundreds of mutations, but only a small fraction produce peptides that can be displayed on the cell surface AND recognized by T cells AND trigger a strong enough immune response to kill tumor cells. Computational algorithms must predict which mutations will produce peptides that fit into HLA molecules (the immune system's display cases) and will be recognized by T cell receptors. Getting this prediction wrong means the vaccine generates an immune response against the wrong targets.

Read the original research

Leveraging mRNA technology for antigen based immuno-oncology therapies.

Journal for immunotherapy of cancer, 13(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Floudas, Charalampos S; Sarkizova, Siranush; Ceccarelli, Michele; Zheng, Wei. (2025). Leveraging mRNA technology for antigen based immuno-oncology therapies.. Journal for immunotherapy of cancer, 13(1). https://doi.org/10.1136/jitc-2024-010569